ATTENTION DEFICIT HYPERACTIVITY DISORDER TREATMENT MARKET ANALYSIS

Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder, mainly occurred in children. ADHD is firstly diagnosed in childhood and often last till adulthood. The most common symptoms of ADHD are children may daydream a lot, forget or loose things, children may have hard time resisting temptation, have trouble taking turns, have difficulty getting along with others, children are overly active, and have trouble paying attention. Attention deficit hyperactivity disorder (ADHD) is treated with stimulant and non-stimulant drugs.

Global attention deficit hyperactivity disorder treatment market is estimated to be valued at US$ 20,183.1 million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030).

Figure 1.Global Attention Deficit Hyperactivity Disorder Treatment Share (%), by Age Group, 2022

To learn more about this report, request sample copy

Global Attention Deficit Hyperactivity Disorder Treatment- Drivers

Increasing prevalence of attention deficit hyperactivity disorder is expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) treatment market during the forecast period. For instance, according to the study titled ‘Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder among Adults and Children of Different Racial and Ethnic Groups’ published in the Journal of the American Medical Association (JAMA Network), in September, 2022, the total number of newly diagnosed patients with ADHD were 838,265 between the year 2010 to 2019. While 121,278 individuals were diagnosed at age of 0 to 6 years in Japan.

Furthermore, key companies focusing on research and development for the treatment of   attention deficit hyperactivity disorder are expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) treatment market during the forecast period. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a U.S. subsidiary, announced positive top-line results from phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.

Figure 2.Global Attention Deficit Hyperactivity Disorder Treatment Share (%), by Region, 2022

To learn more about this report, request sample copy

Global Attention Deficit Hyperactivity Disorder Treatment– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another. Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in more than 622,389,418 confirmed cases infected individuals worldwide as of 18 October, 2022.

Furthermore, psychological behavior in attention deficit hyperactivity disorder (ADHD) patients has worsen due to COVID-19 pandemic. For instance, according to the study published in the child and adolescent health, in THE LANCET journal, on April 17, 2020, it was found that during COVID-19 pandemic, the patients suffering from attention deficit hyperactivity disorder (ADHD) have become more vulnerable due to the stress caused by the pandemic. Thus due to COVID-19 has negatively impacted the patients of ADHD .

 Global Attention Deficit Hyperactivity Disorder Treatment: Key Developments

In September 19, 2022, Cingulate, a biopharmaceutical company that focused on the development of new product candidates for the treatment of central nervous system and neurobiological disorders, presents data for its product candidate called CTx-2103, an extended release tablet of busporin used for treatment of anxiety related disease like attention deficit hyperactivity disorder in children as well as adults.

In July 2021, Adlon Treatment L.P., a subsidiary of Purdue Pharma L.P., is a specialty pharmaceutical company committed to provide treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD), announced the approval of supplement new drug application for ADHANSIA XR(methylphenidate HCI) extended release capsules CII for treatment of ADHD. ADHANSIA XR capsule contains multilayered beads, composed of immediate release layer and 20 percent of methylphenidate dose.

Global Attention Deficit Hyperactivity Disorder Treatment: Restraint

The major factors that hinder growth of the global attention deficit hyperactivity disorder treatment market include high cost of attention deficit hyperactivity disorder drugs. Costs of attention deficit hyperactivity disorder drugs are quite high as these need research and development process, and their manufacturing is a very complex process, which needs highly skilled scientists. Such expensive biopharmaceutical drugs and medications are not affordable to organizations and hospitals such a Morris Foundation, education and health foundation (AMF) offering assessment and remedial educational assistance to students with Specific Learning Disabilities (SLDs) and Attention Deficit Hyperactivity Disorder (ADHD), India, in emerging economies such as India, China, etc. High cost of attention deficit hyperactivity disorder medication is a major factor hindering its adoption. For instance, in February 2022, a paper was published by National Center for Biotechnology Information, according to which from the year 2010 to 2019 sampled prescription for ADHD medications increased from US$ 125.29 to US$ 529.36 in China. Thus it was concluded that ADHD drugs and the corresponding increase in cost is increasing rapidly

Global Attention Deficit Hyperactivity Disorder Treatment market- Key Players

Major players operating in the global attention deficit hyperactivity disorder treatment market include Amnel Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P. ,Cingulate, Adlon Therapeutics L.P., Tris Pharma, Inc.,Neuraxpharm, Supernus Pharmaceuticals,Inc., and Aytu Biopharma, Inc.